Keep up to date with latest news and analyses from PCSK9 inhibitor trials.
For expert analysis and insights
Lerodalcibep: What does LIBerate-HeFH tell us?
Professor Derick Raal discusses lerodalcibep data from the LIBerate-HeFH trial and explains what the results mean to practising clinicians.
Related content: